Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.
Treatment options for triple negative breast cancer (TNBC) are generally limited to cytotoxic chemotherapy. Recently, anti-epidermal growth factor receptor (EGFR) therapy has been introduced for TNBC patients. We engineered a novel nanobioconjugate based on a poly(β-L-malic acid) (PMLA) nanoplatform...
Main Authors: | Satoshi Inoue, Rameshwar Patil, Jose Portilla-Arias, Hui Ding, Bindu Konda, Andres Espinoza, Dmitriy Mongayt, Janet L Markman, Adam Elramsisy, H Westley Phillips, Keith L Black, Eggehard Holler, Julia Y Ljubimova |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3280290?pdf=render |
Similar Items
-
Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer
Published: () -
Cellular Delivery of Doxorubicin via pH-Controlled Hydrazone Linkage Using Multifunctional Nano Vehicle Based on Poly(β-L-Malic Acid)
by: Keith L. Black, et al.
Published: (2012-09-01) -
Quantitative Analysis of PMLA Nanoconjugate Components after Backbone Cleavage
by: Hui Ding, et al.
Published: (2015-04-01) -
Polymalic Acid Tritryptophan Copolymer Interacts with Lipid Membrane Resulting in Membrane Solubilization
by: Hui Ding, et al.
Published: (2017-01-01) -
Nanoconjugate Platforms Development Based in Poly(β,L-Malic Acid)
Methyl Esters for Tumor Drug Delivery
by: José Portilla-Arias, et al.
Published: (2010-01-01)